Tempest Therapeutics Finalizes Prospectus for Resale of 2.78M Shares, Securing Potential $4M from Warrants
TPST is trading near its 52-week low of $1.5 (6.0% above the low).
Summary
Tempest Therapeutics filed a final prospectus for the resale of up to 2.78 million shares by selling stockholders, including an entity linked to the CEO, which also details warrants that could generate approximately $4 million for the company upon exercise.
Key Events · Financing and Capital Events · TPST
-
Finalizes Resale Offering
This 424B3 prospectus finalizes the resale of 2,777,781 shares of common stock by selling stockholders, including shares underlying warrants. This follows the S-3 registration statement filed on April 2, 2026.
-
Potential Capital Infusion from Warrants
The company stands to receive approximately $4 million from the cash exercise of Series A and Series B Warrants, which have an exercise price of $2.16 per share, above the current market price of $1.59.
-
Significant Dilution Impact
The resale of 2,777,781 shares represents a potential dilution of approximately 19.4% of the company's outstanding common stock.
-
CEO-Affiliated Entity Participation
Factor Bioscience Inc., an entity where CEO Dr. Matthew Angel is a majority equityholder, participated in the initial private placement, acquiring shares and warrants for over $500,000.
Analysis · TPST · Life Sciences
This 424B3 filing finalizes the terms for the resale of up to 2.78 million shares by selling stockholders, following an S-3 registration statement filed on April 2, 2026. While the company will not receive direct proceeds from the resale of these shares, it stands to gain approximately $4 million from the exercise of associated Series A and Series B Warrants. Notably, these common warrants have an exercise price of $2.16 per share, which is a premium to the current stock price of $1.59, indicating investor confidence in future appreciation. This capital infusion is critical for Tempest Therapeutics, especially given its recent 'going concern' warning disclosed in the March 30, 2026 10-K filing. The participation of Factor Bioscience Inc., an entity where the CEO is a majority equityholder, in the initial private placement further signals internal conviction, despite the dilutive effect of the overall offering.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.6% of the 1569 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TPST was trading at $1.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.7M. The 52-week trading range was $1.50 to $12.23. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.